Exendin-(9-39)

ApprovedSmall molecule

EEiger BioPharmaceuticals

Exendin-(9-39) is one of 187 small molecule programs targeting Hyperinsulinism. It is currently in Approved.

Indications

Total Trials

Active Trials

186

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperinsulinismActive, not recruiting

Insulin SecretionActive, not recruiting

Type 2 Diabetes MellitusApproved

Diabetes MellitusActive, not recruiting

HypoglycemiaActive, not recruiting

Hyperinsulinemic HypoglycemiaActive, not recruiting

Type 2 DiabetesActive, not recruiting

GrowthActive, not recruiting

HyperinsulinismPhase 1/Phase 2

Active, not recruiting

Insulin SecretionPhase 1

Active, not recruiting

Type 2 Diabetes MellitusApproved

Approved

Diabetes MellitusPhase 2

Active, not recruiting

HypoglycemiaPreclinical

Active, not recruiting

Hyperinsulinemic HypoglycemiaPhase 1

Active, not recruiting

Type 2 DiabetesApproved

Active, not recruiting

GrowthApproved

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Exendin-(9-39)

EEiger BioPharmaceuticals

Approved

1 2

Byetta

AstraZeneca

Preclinical

55 3

Jardiance

Boehringer Ingelheim

Preclinical

31 4

NOVOLIN R

Novo Nordisk

Preclinical

5 5

Aurlumyn

BBTG International Inc.

Preclinical

1 6

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 7

Lovaza

AstraZeneca

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

2 10

GLP-1

RRigshospitalet, Denmark

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Insulin Secretion

NCT00992901

Phase 1Recruiting

Metabolism

NCT01803451

Phase 1Recruiting

Metabolism

NCT02823665

Q1 2028

Phase 2Recruiting

Prediabetes

NCT06967558

Q1 2029

Phase 2Not yet recruiting

Humans

NCT06972407

Clinical

Trials by Indication[1]

Insulin Secretion3 trials

Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT00992901·160 enrolled

Incretin Regulation of Insulin Secretion in Monogenic Diabetes

Completed·UUniversity of Chicago·Phase 1·NCT01795144·10 enrolled

Regulation of Insulin Secretion by the GLP-1 Receptor

Terminated·VVA Office of Research and Development·Phase 4·NCT02844907·6 enrolled

Metabolism3 trials

Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT01803451·80 enrolled

The Effects of Bariatric Surgeries on Glucose Metabolism

Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT02823665·200 enrolled

The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass

Completed·AAdrian Vella·Phase 1·NCT01843881·20 enrolled

Hypoglycemia3 trials

Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

Completed·EEiger BioPharmaceuticals·Phase 2·NCT03373435·18 enrolled

Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia

Completed·DDiva De Leon·N/A·NCT01162499·7 enrolled

Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia

Completed·TTracey McLaughlin·Phase 1·NCT02996812·9 enrolled

Humans2 trials

The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans

Not yet recruiting·MMayo Clinic·Phase 2·NCT06972407·80 enrolled

Intestinal Glucagon-like Peptide-1 (GLP-1) and the Physiological Role in Eating in Humans

Completed·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT01900340·12 enrolled

Hyperinsulinism1 trial

Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism

Completed·DDiva De Leon·Phase 1/2·NCT00571324·9 enrolled

14 more indications

Hyperinsulinemic Hypoglycemia1 trial

Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric Surgery

Terminated·TTracey McLaughlin·Phase 1·NCT02550145·10 enrolled

CAR1 trial

Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small Intestines

Completed·UUniversity Hospital, Gentofte, Copenhagen·N/A·NCT03241303·15 enrolled

Function1 trial

Ghrelin Effect on Beta Cell Function in Health and Disease

Unknown status·DDavid Dalessio·N/A·NCT01729299·30 enrolled

Conditioning1 trial

Glucagon Like Peptide-1 in Remote Ischemic Conditioning

Completed·KKarolinska Institutet·N/A·NCT02746757·12 enrolled

Diabetes Mellitus1 trial

Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus

Completed·MMayo Clinic·Phase 2·NCT02170870·104 enrolled

Gastric Bypass Surgery1 trial

Influence of Gut Hormones on Food Intake After Roux-en-Y Gastric Bypass Surgery

Completed·HHvidovre University Hospital·N/A·NCT02336659·12 enrolled

Cardiovascular1 trial

Cardiovascular Effects of GLP-1 Receptor Activation

Completed·VVanderbilt University Medical Center·Phase 4·NCT03101930·329 enrolled

AIN1 trial

Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia

Terminated·DDiva De Leon·Phase 1/2·NCT00835328·14 enrolled

PreDiabetes1 trial

The Role of Islet GLP-1 in the Pathogenesis of Prediabetes

Recruiting·MMayo Clinic·Phase 2·NCT06967558·60 enrolled

Growth1 trial

Effect of DPP4 Inhibition on Growth Hormone Secretion

Completed·VVanderbilt University·Phase 4·NCT01701973·44 enrolled

Metformin1 trial

The Role of GLP-1 Receptor Signalling in the Glucose-lowering Effect of Metformin in Patients With T2D

Completed·UUniversity Hospital, Gentofte, Copenhagen·N/A·NCT03246451·15 enrolled

Type 2 Diabetes1 trial

GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes

Completed·DDiabeteszentrum Bad Lauterberg im Harz·Phase 4·NCT02639130·67 enrolled

Type 2 Diabetes Mellitus1 trial

Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus

Completed·LLudwig-Maximilians - University of Munich·Phase 1·NCT00551590·24 enrolled

Unspecified1 trial

Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity

Completed·DDiva De Leon·Phase 1/2·NCT00897676·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 26 trial records for Exendin-(9-39). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Exendin-(9-39) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Exendin-(9-39). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eiger BioPharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: EEiger BioPharmaceuticals

Exendin-(9-39)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q1 2028

Q1 2029

Trials by Indication[1]

Insulin Secretion3 trials

Metabolism3 trials

Hypoglycemia3 trials

Humans2 trials

Hyperinsulinism1 trial

Hyperinsulinemic Hypoglycemia1 trial

CAR1 trial

Function1 trial

Conditioning1 trial

Diabetes Mellitus1 trial

Gastric Bypass Surgery1 trial

Cardiovascular1 trial

AIN1 trial

PreDiabetes1 trial

Growth1 trial

Metformin1 trial

Type 2 Diabetes1 trial

Type 2 Diabetes Mellitus1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News